Antidiabetic therapy of type-2 diabetes;Antidiabetische therapie bei Typ-2 diabetes

Wiener Klinische Wochenschrift

Volumn 121, Issue SUPPL.5, 2009, Pages

  Clodi, Martin ^a   Fasching, Peter ^b   Hoppichler, Friedrich ^c   Kautzky Willer, Alexandra ^a   Lechleitner, Monika ^d   Ludvik, Bernhard ^a   Prager, Rudolf ^e   Roden, Michael ^f   Schernthaner, Guntram ^g   Toplak, Hermann ^h   Wascher, Thomas C ⁱ   Weitgasser, Raimund ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^d Anna Dengel Haus   (Austria)

^e Neurologisches Krankenhaus der Stadt Wien   (Austria)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ HANUSCH HOSPITAL   (Austria)

^j Univ Klinik für Innere Medizin i   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIQUIDONE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

AUSTRIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY;

EID: 75449119649     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 352: 837-853
2. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865
3. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR (2004) Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 27: 201-207
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (15): 1577-1589
5. ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (24): 2560-2572
6. Action to control cardiovascular risk in diabetes study group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2): 129-139
8. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (9677): 1765-1772
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (9493): 1279-1289
10. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators (2007) The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (17): 1772-1780
11. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (3): 865-873
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (10): 1180-1188
13. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (9681): 2125-2135
14. BARI 2D Study Group (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (24): 2503-2515
15. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16